Business Description
Fennec Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA31447P1009
Compare
Compare
Traded in other countries / regions
FENC.USAFRX.CanadaRV41.Germany IPO Date
2001-06-04Description
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.59 | |||||
| Equity-to-Asset | -0.5 | |||||
| Debt-to-Equity | -2.61 | |||||
| Debt-to-EBITDA | -1.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -14.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -11 | |||||
| 3-Year EPS without NRI Growth Rate | -13.2 | |||||
| 3-Year FCF Growth Rate | -15.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.52 | |||||
| 9-Day RSI | 39.94 | |||||
| 14-Day RSI | 38.3 | |||||
| 6-1 Month Momentum % | -0.54 | |||||
| 12-1 Month Momentum % | -1.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.12 | |||||
| Quick Ratio | 4.74 | |||||
| Cash Ratio | 3.96 | |||||
| Days Inventory | 1469.67 | |||||
| Days Sales Outstanding | 105.79 | |||||
| Days Payable | 3768.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.8 | |||||
| Shareholder Yield % | -8.32 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.28 | |||||
| Operating Margin % | -368.02 | |||||
| Net Margin % | -404.85 | |||||
| ROA % | -116.57 | |||||
| ROIC % | -5242.55 | |||||
| ROC (Joel Greenblatt) % | -4078.63 | |||||
| ROCE % | -125.82 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 23.15 | |||||
| PS Ratio | 29.81 | |||||
| EV-to-EBIT | -8.56 | |||||
| EV-to-EBITDA | -8.59 | |||||
| EV-to-Revenue | 31.43 | |||||
| EV-to-Forward-Revenue | 4.11 | |||||
| EV-to-FCF | -9.83 | |||||
| Earnings Yield (Greenblatt) % | -11.67 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fennec Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 8.798 | ||
| EPS (TTM) (C$) | -1.348 | ||
| Beta | -0.15 | ||
| Volatility % | 36.83 | ||
| 14-Day RSI | 38.3 | ||
| 14-Day ATR (C$) | 0.162885 | ||
| 20-Day SMA (C$) | 10.3005 | ||
| 12-1 Month Momentum % | -1.95 | ||
| 52-Week Range (C$) | 9.59 - 14.41 | ||
| Shares Outstanding (Mil) | 26.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fennec Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fennec Pharmaceuticals Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fennec Pharmaceuticals Inc Frequently Asked Questions
What is Fennec Pharmaceuticals Inc(TSX:FRX)'s stock price today?
The current price of TSX:FRX is C$9.87. The 52 week high of TSX:FRX is C$14.41 and 52 week low is C$9.59.
When is next earnings date of Fennec Pharmaceuticals Inc(TSX:FRX)?
The next earnings date of Fennec Pharmaceuticals Inc(TSX:FRX) is 2023-11-10 Est..
Does Fennec Pharmaceuticals Inc(TSX:FRX) pay dividends? If so, how much?
Fennec Pharmaceuticals Inc(TSX:FRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers